With the enormous leaps in medical advancements over the past decades, previously career-ending injuries are now being rehabbed more efficiently and effectively through the use of technology and ...

Proteus Digital Health gained FDA de novo clearance for a new ingestible sensor designed to be combined with a drug, capping a four-year process of working with regulators to find the best approval ...

The Proteus Device from XXLSEC is a handheld computer with a 5 inch touchscreen display and a secure, Linux-based operating system called PriveOS. At first glance, it looks a lot like a smartphone.

Otsuka and partner Proteus Digital Health envisioned a new version of the antipsychotic Abilify that could track patients and their doses. But the FDA was underwhelmed by the partners' ...

The US Food and Drug Administration (FDA) has cleared an ingestible medical device manufactured by Proteus Digital Health through its de novo clearance pathway, clearing the way for the futuristic ...

Proteus Digital Health and partner Otsuka have submitted an application to the FDA for approval of their innovative drug adherence device, a milestone for Proteus months after scoring the agency's ...

The Proteus Device from XXLSEC is a handheld computer with a 5 inch touchscreen display and a secure, Linux-based operating system called PriveOS. At first glance, it looks a lot like a smartphone.

Last year, the FDA approved Proteus Digital Health's ingestible biosensor for monitoring drug compliance. The technology blurred the line between the world of pharmaceuticals and medical devices in ...

Proteus and Otsuka expect to hear back from the FDA by Q4 of this year. Assuming the approval goes through, Otsuka could begin selling the drug shortly thereafter. Subsequent approvals of embedded ...

REDWOOD CITY, Calif.--(EON: Enhanced Online News)--Proteus Biomedical Inc., a pioneer in intelligent medicine, announced today that the United States Patent Office awarded U.S. Patent Number 7,978,064 ...